SB 242235

Name: SB 242235
Brand: MedChemExpress
SKU: HY-18306
Rating: 5.0 (2 reviews)

Cat. No.: HY-18306 Purity: 99.51%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC₅₀ of 1.0　μM in primary human chondrocytes.

For research use only. We do not sell to patients.

SB 242235 Chemical Structure

CAS No. : 193746-75-7

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 94	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 94	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 85	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 145	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 305	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 520	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 880	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

2 Publications Citing Use of MCE SB 242235

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK p38α p38β MAPK13 p38δ p38γ

Biological Activity
Purity & Documentation
References
Customer Review

Description

SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC₅₀ of 1.0　μM in primary human chondrocytes^[1].

IC₅₀ & Target

IC50: 1.0　μM (p38 MAPK, primary human chondrocytes)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
PBMC	IC₅₀	170 nM Compound: SB-242235	Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA	[PMID: 18602262]

In Vitro

SB 242235 (0-10　μM) dose-dependently inhibits the activation of MAPKAP K2 with an IC₅₀ of 1.0 μM in human chondrocytes stimulated with IL-1β^[1].
SB 242235 inhibits intracellular p38 activity, MAPKAP K2 was then isolated from these cells and assayed using HSP27 as a substrate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Human chondrocytes
Concentration:	0 μM,0.01 μM,0.1 μM,1 μM,10　μM
Incubation Time:	15 minutes
Result:	Dose-dependently inhibited the activation of MAPKAP K2 with an IC₅₀ of 1.0 μM.

In Vivo

SB242235 (100 mg/kg; p.o.) abolishes MAP-KAPK-2 activity and HSP27 phosphorylation^[2].
SB242235 inhibits expression of the pro-inflammatory cytokines interleukin (IL)-6 and KC (murine IL-8) and COX-2^[2].
SB-242235 is demonstrated non-linear elimination kinetics that manifested as a decrease in clearance with increasing dose and apparent oral bioavailability > 100% at high oral doses in rat and monkey^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female SKH-1 hairless mice (4–6 weeks)^[2]
Dosage:	100 mg/kg
Administration:	Oral administered, 30 minutes prior to ultraviolet B (UVB) irradiation
Result:	Abolished MAP-KAPK-2 activity and heat shock protein 27 (HSP27) phosphorylation.

Molecular Weight

353.39

Formula

C₁₉H₂₀FN₅O

CAS No.

193746-75-7

Appearance

Solid

Color

White to off-white

SMILES

COC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCNCC4)=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 48 mg/mL (135.83 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8297 mL	14.1487 mL	28.2973 mL
5 mM	0.5659 mL	2.8297 mL	5.6595 mL
10 mM	0.2830 mL	1.4149 mL	2.8297 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.07 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.51%

Select Batch:

Data Sheet (281 KB) SDS (393 KB)

COA (256 KB) LCMS (268 KB)

Handling Instructions (2659 KB)

References

[1]. Badger, A.M., et al., Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures. Osteoarthritis Cartilage, 2000. 8(6): p. 434-43. [Content Brief]

[2]. Kim AL , et al. Role of p38 MAPK in UVB-induced inflammatory responses in the skin of SKH-1 hairless mice. J Invest Dermatol. 2005 Jun;124(6):1318-25. [Content Brief]

[3]. Ward, K.W., et al., SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics. Xenobiotica, 2002. 32(3): p. 221-33. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8297 mL	14.1487 mL	28.2973 mL	70.7434 mL
	5 mM	0.5659 mL	2.8297 mL	5.6595 mL	14.1487 mL
	10 mM	0.2830 mL	1.4149 mL	2.8297 mL	7.0743 mL
	15 mM	0.1886 mL	0.9432 mL	1.8865 mL	4.7162 mL
	20 mM	0.1415 mL	0.7074 mL	1.4149 mL	3.5372 mL
	25 mM	0.1132 mL	0.5659 mL	1.1319 mL	2.8297 mL
	30 mM	0.0943 mL	0.4716 mL	0.9432 mL	2.3581 mL
	40 mM	0.0707 mL	0.3537 mL	0.7074 mL	1.7686 mL
	50 mM	0.0566 mL	0.2830 mL	0.5659 mL	1.4149 mL
	60 mM	0.0472 mL	0.2358 mL	0.4716 mL	1.1791 mL
	80 mM	0.0354 mL	0.1769 mL	0.3537 mL	0.8843 mL
	100 mM	0.0283 mL	0.1415 mL	0.2830 mL	0.7074 mL

SB 242235 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

SB 242235193746-75-7SB242235SB-242235p38 MAPKAutophagyInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

SB 242235

Customer Review

SB 242235 Related Antibodies

2 Publications Citing Use of MCE SB 242235

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

SB 242235 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

SB 242235 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report